ALGS
Aligos Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.24
+1.35%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$2.44
- Revenue estimate
- $4.8M
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.14
- EPS estimate
- -$1.09
- Revenue actual
- $27.8M
- Revenue estimate
- $24.7M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +13.5%
- Revenue beats (12Q)
- 9
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | -$1.09 | -$0.14 | Beat 87.16% | $27.8M |
| May 7, 2026 | -$2.29 | -$2.21 | Beat 3.49% | $2.8M |
| Mar 5, 2026 | -$2.09 | -$1.91 | Beat 8.61% | $169.0K |
| Nov 6, 2025 | -$2.09 | -$3.04 | Miss -45.45% | $741.0K |
| Mar 10, 2025 | -$2.63 | -$3.41 | Miss -29.66% | $629.0K |
| Mar 12, 2024 | -$6.75 | -$5.50 | Beat 18.52% | $2.7M |
| Nov 2, 2023 | -$12 | -$10 | Beat 14.58% | $3.2M |
| Aug 3, 2023 | -$13 | -$11 | Beat 14.00% | $6.9M |
| May 4, 2023 | -$12 | -$13 | Miss -8.16% | $2.7M |
| Mar 9, 2023 | -$12 | -$13 | Miss -4.08% | $3.5M |
| Nov 2, 2022 | -$14 | -$11 | Beat 22.81% | $4.1M |
| Aug 4, 2022 | -$16 | -$12 | Beat 27.69% | $3.7M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026